Case number 1:24-cv-00138
Bayer Pharma AG et al v. Lupin Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 9, 2024 | N/A | CORRECTING ENTRY: The Answer to Counterclaims filed at D.I. 15 on 4/9/2024, has been removed from the docket as it was filed in error. (nms) (Entered: 04/09/2024) (0) |
| Apr 2, 2024 | 14 | SO ORDERED Granting (D.I. 162 in 21-cv-314-RGA-LDH; D.I. 13 in 24-cv-138-RGA; D.I. 255 in 21-md-3017-RGA-LDH) Stipulation and Order Regarding Consolidation and Schedule. Signed by Judge Richard G. Andrews on 4/2/2024. Associated Cases: 1:21-md-03017-RGA-LDH, 1:21-cv-00314-RGA-LDH, 1:24-cv-00138-RGA(nms) (Entered: 04/02/2024) (4) |
| Apr 1, 2024 | 13 | STIPULATION and Order Regarding Consolidation and Schedule - by Bayer AG, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) (Entered: 04/01/2024) (4) |
| Mar 19, 2024 | N/A | CORRECTING ENTRY: The Answer filed at D.I. 10, the 7.1 Disclosure statement at D.I. 11, and Notice of Appearance filed at D.I. 12 all filed on 3/19/2024, have been removed from the docket. This case is a member case to MDL 21-3017-RGA and therefore all filings require in the case caption reference to the MDL and the underlying member case. Counsel is to amend all documents and refile accordingly. (nms) (Entered: 03/19/2024) (0) |
| Mar 19, 2024 | 10 | ANSWER to 1 Complaint, Affirmative Defenses, and COUNTERCLAIMS against All Plaintiffs, by Lupin Pharmaceuticals, Inc., Lupin Limited.(Haney, Megan) Modified on 3/19/2024 (nms). (Entered: 03/19/2024) (26) |
| Mar 19, 2024 | 11 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Limited for Lupin Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc. filed by Lupin Limited, Lupin Pharmaceuticals, Inc.. (Haney, Megan) (Entered: 03/19/2024) (2) |
| Mar 19, 2024 | 12 | NOTICE of Appearance by Megan C. Haney on behalf of Lupin Limited, Lupin Pharmaceuticals, Inc. (Haney, Megan) (Entered: 03/19/2024) (1) |
| Feb 29, 2024 | 8 | SUMMONS Returned Executed by Bayer Pharma AG, Janssen Pharmaceuticals, Inc., Bayer AG.Lupin Limited served on 2/27/2024, answer due 3/19/2024. (Fahnestock, Derek) (Entered: 02/29/2024) (2) |
| Feb 29, 2024 | 9 | SUMMONS Returned Executed by Bayer Pharma AG, Janssen Pharmaceuticals, Inc., Bayer AG.Lupin Pharmaceuticals, Inc. served on 2/27/2024, answer due 3/19/2024. (Fahnestock, Derek) (Entered: 02/29/2024) (2) |
| Feb 7, 2024 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 02/07/2024) (0) |
| Feb 2, 2024 | 1 | COMPLAINT filed against Lupin Limited, Lupin Pharmaceuticals, Inc. ( Filing fee $ 405, receipt number ADEDC-4329152.) - filed by Bayer Pharma AG, Janssen Pharmaceuticals, Inc., Bayer AG. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(apk) (Entered: 02/02/2024) (0) |
| Feb 2, 2024 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (apk) (Entered: 02/02/2024) (3) |
| Feb 2, 2024 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/22/2023. Date of Expiration of Patent: SEE ANDA FORM. (apk) (Entered: 02/02/2024) (1) |
| Feb 2, 2024 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,828,310 B2. (apk) (Entered: 02/02/2024) (1) |
| Feb 2, 2024 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bayer AG for Bayer Pharma AG filed by Bayer AG, Bayer Pharma AG. (apk) (Entered: 02/02/2024) (1) |
| Feb 2, 2024 | 6 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceuticals, Inc. filed by Janssen Pharmaceuticals, Inc.. (apk) (Entered: 02/02/2024) (1) |
| Feb 2, 2024 | 7 | Summons Issued as to Lupin Limited on 2/2/2024; Lupin Pharmaceuticals, Inc. on 2/2/2024. (Attachments: # 1 Summons Issued)(apk) (Entered: 02/02/2024) (0) |
| Feb 2, 2024 | N/A | Remark: MDL Panel has been Notified (apk) (Entered: 02/02/2024) (0) |
